Cefpiran治疗泌尿生殖系感染的多中心临床研究

A multicentre clinical study on cefpiran in the treatment of urogenital tract infections

下载PDF

导出

摘要为评价ｃｅｆｐｉｒａｎ在治疗泌尿生殖系感染中的有效性和安全性，我们在多中心临床应用ｃｅｆｐｉｒａｎ开放性治疗各类泌尿生殖系感染３０例。用药剂量为１ｇ，静脉点滴，疗程５～７ｄ。结果：对急性单纯性尿路感染，使用ｃｅｆｐｉｒａｎ后，治愈率为７８．６％（１１／１４），有效率达１００％（１４／１４）；对慢性复杂性尿路感染，治愈率为７０％（７／１０），有效率为８０％（８／１０）。总治愈率为７３．３％（２２／３０），总有效率为９０％（２７／３０）。不良反应发生率为６．７％。细菌清除率为８２．１％（２３／２８）。本研究结果表明，ｃｅｆｐｉｒａｎ是治疗泌尿生殖系感染的一种有效、安全的新型抗菌药物。 To evaluate the efficacy and safety of cefpiran in the treatment of urogenital tract infections, 30 patients with various kinds of urogenital tract infections were treated with the drug in an opened trial in three hospitals. Cefpiran was intravenously administered 1g daily for 5~7 days. Results showed that for simple urinary tract infections, the cure rate was 78.6% (11/14), the effective rate was 100% (14/14); for complicated urinary tract infections, the cure rate and the effective rate were 70% (7/10) and 80% (8/10) respectively. Overall, the total cure rate, effective rate and the bacterial eradication rate were 73.3% (22/30), 90% (27/30) and 82.1% (23/28) respectively. Adverse events attributed to drug treatment occurred in two patients (6.7%). Additionally, cefpiran was not contraindicated for patients with even moderately impaired renal function. It was concluded that cefpiran is an effective and safe antibiotic for patients with urogenital tract infections.